• Users Online: 69
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2020  |  Volume : 3  |  Issue : 1  |  Page : 12-18

Mitochondrial DNA content in tumor tissue and blood of patients with glioblastoma – A reliable biomarker?


1 Department of Clinical Neurosciences, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
2 Department of Radiation Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
3 Department of Neuropathology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
4 Neurosurgery, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India

Correspondence Address:
Dr. Arivazhagan Arimappamagan
Department of Neurosurgery, National Institute of Mental Health and Neurosciences, Hosur Road, Bengaluru, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/IJNO.IJNO_12_20

Rights and Permissions

Introduction: Recent studies have shown that mitochondrial DNA (mtDNA) content in the tumor tissue is associated with patient survival in glioblastoma (GBM). However, mtDNA content in the blood of patients with GBM and its variation during treatment has not been documented. Hence, we assessed mtDNA content in blood and tumor tissue of GBM patients, its association with survival, and the variation of mtDNA content in blood with treatment. Materials and Methods: GBM tissue obtained from 20 patients, 2 ml blood collected from the same patients at the time of presentation and following radiation therapy (RT), 2 ml blood obtained from 20 healthy volunteers were assessed for mtDNA content using quantitative real-time polymerase chain reaction (comparative ct method). The mtDNA content is expressed as the mtDNA/nuclear gene ratio. Results: The mean mtDNA copy number in the GBM tissue was 492.3819, while in the blood of patients, it was 41.76 ± 19.45. In healthy volunteers' blood, it was 55.97 ± 5.78 (P = 0.04). The median overall survival was 13 months in patients with high tumor mtDNA content and 10 months in patients with low tumor mtDNA content (P = 0.04). Patients with low-mtDNA content in the blood had a relatively higher content in the tumor tissue (correlation coefficient − 0.26; P = 0.27). No significant difference was noted between mtDNA content in preoperative blood (41.76 ± 19.45) and post-RT blood sample (44.16 ± 12.83) (P = 0.6). Conclusion: High GBM tumor mtDNA copy number is associated with better overall survival. mtDNA content in the blood is lower in GBM patients when compared with healthy volunteers. mtDNA content in the blood of the patients did not vary following surgery and RT.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed692    
    Printed67    
    Emailed0    
    PDF Downloaded119    
    Comments [Add]    

Recommend this journal